Oncopeptides AB (publ) (ONPPF) Q4 2025 Sales/Trading Call Transcript

Core Viewpoint - Oncopeptides reported strong sales growth in Q4 2025, with net sales reaching SEK 18.6 million, reflecting an 88% increase year-over-year compared to Q4 2024 and a 125% increase compared to the full year of 2024 [2]. Sales Performance - The company achieved significant year-over-year growth across all key markets, particularly in Italy, which exceeded expectations [2]. - Germany, the largest market, experienced double-digit growth; however, this was not enough to offset the negative impact from Spain due to a strike among medical doctors [3]. Financial Outlook - Based on the current run rate, Oncopeptides has recalibrated its financial expectations, now anticipating cash flow positivity to occur in 2027 instead of the previously projected end of 2026 [4]. - The company remains confident in the long-term value of its European business despite the adjustments to its financial timeline [4].